Figure 3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Year: 2024
Type: other
Abstract: Gene mutations by race. A, Percentage of tumors from Black versus White patients that are positive for the indicated gene mutations. #, P < 0.001; ns, not significant. B–E, Probability of Black patients having a TP53 (B), APC (C), KRAS (D), or PIK3CA (E) mutation relative to White patients for each individual tumor type. *, P < 0.05; #, P < 0.001. When data are not shown, we did not produce confidence intervals because of low gene mutation prevalence for the indicated cancer type.
Authors: Elisabeth Heath, Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani, Mohammed N. Al-Hallak, Anthony F. Shields, Jailan A. Elayoubi, Ira S. Winer, Frank C. Cackowski, Gary A. Puckrein, Gilberto de Lima Lopes, Nathaniel Jones, Ralph J. Hauke, Samuel A. Kareff, Milan Radovich, George W. Sledge, David B. Spetzler, Gregory A. Vidal, John L. Marshall
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4403136185